Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials

被引：0
|
作者：
Ritchlin, Christopher T. [1 ]
Rahman, Proton [2 ]
Helliwell, Philip S. [3 ]
Boehncke, Wolf-Henning [4 ]
McInnes, Iain [5 ]
Gottlieb, Alice B. [6 ]
Kollmeier, Alexa P. [7 ]
Shawi, May [8 ]
Zhou, Bei [7 ]
Mease, Philip J. [9 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] Mem Univ Newfoundland, St John, NF, Canada
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Geneva Univ Hosp, Geneva, Switzerland
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[7] Janssen Res & Dev LLC, Raritan, NJ USA
[8] Janssen Global Serv LLC, Raritan, NJ USA
[9] Univ Washington, Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA 98195 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27529
引用
收藏
页码：AB151 / AB151
页数：1
相关论文
共 50 条
  • [21] Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and-2 Randomized Clinical Trials
    Mease, Philip
    Korotaeva, Tatiana
    Shesternya, Pavel
    Kokhan, Muza
    Rukavitsyn, Anton
    Vasilchenkov, Dmitry
    Sharaf, Mohamed
    Lavie, Frederic
    Deodhar, Atul
    RHEUMATOLOGY AND THERAPY, 2024, 11 (06) : 1551 - 1567
  • [22] Guselkumab Provides Sustained Improvements in Work Productivity and Daily Activity in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
    Curtis, Jeffrey
    McInne, Iain B.
    Rahman, Proton
    Gladman, Dafna
    Yang, Feifei
    Peterson, Steve
    Kollmeier, Alexa
    Shiff, Natalie
    Han, Chenglong
    Shawi, May
    Tillett, William
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1014 - 1016
  • [23] GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 2 YEARS OF DISCOVER-2
    Curtis, J.
    Mcinnes, I.
    Rahman, P.
    Gladman, D. D.
    Yang, F.
    Peterson, S.
    Kollmeier, A.
    Shiff, N.
    Han, C.
    Shawi, M.
    Tillett, W.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1568 - 1569
  • [24] GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 2 YEARS OF DISCOVER-2
    Curtis, J.
    McInnes, I.
    Rahman, P.
    Gladman, D. D.
    Yang, F.
    Peterson, S.
    Kollmeier, A.
    Shiff, N.
    Han, C.
    Shawi, M.
    Tillett, W.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1563 - 1564
  • [25] Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients with Active Psoriatic Arthritis Through 2 Years of DISCOVER-2
    Curtis, Jeffrey
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna
    Yang, Feifei
    Peterson, Steve
    Kollmeier, Alexa
    Shiff, Natalie
    Han, Chenglong
    Shawi, May
    Tillett, William
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3651 - 3653
  • [26] Efficacy of guselkumab across components of the Bath Ankylosing Spondylitis Disease Activity Index and the Ankylosing Spondylitis Disease Activity Score in improving symptoms of axial manifestations of active psoriatic arthritis: pooled data from two phase III randomized, placebo-controlled studies (DISCOVER-1 and DISCOVER-2)
    Behrens, F.
    Mease, P.
    Helliwell, P.
    Shawi, M.
    Noel, W.
    Chakravarty, S.
    Kollmeier, A.
    Xu, X.
    Xu, S.
    Wang, Y.
    Baraliakos, X.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E50 - E51
  • [27] Effects of guselkumab on articular components of American College of Rheumatology score and skin responses in patients with active psoriatic arthritis: Results from the phase 3 DISCOVER-2 study
    Gottlieb, Alice B.
    Mease, Philip J.
    Merola, Joseph F.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Agarwal, Prasheen
    van der heijde, Desiree
    McInnes, Iain B.
    Boehncke, Wolf-Henning
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145
  • [28] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    van der Heijde, Desiree
    McInnes, Iain B.
    LANCET, 2020, 395 (10230): : 1126 - 1136
  • [29] The Effect of Guselkumab on Work Productivity in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Curtis, Jeffrey R.
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna D.
    Peterson, Steven
    Agarwal, Prasheen
    Yang, Feifei
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Shiff, Natalie J.
    Zhou, Bei
    Han, Chenglong
    Shawi, May
    Tillett, William
    Mease, Philip J.
    ADVANCES IN THERAPY, 2022, 39 (10) : 4613 - 4631
  • [30] Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial
    Orbai, Ana-Maria
    Coates, Laura
    Deodhar, Atul
    Helliwell, Philip S.
    Ritchlin, Christopher
    Kollmeier, Alexa
    Hsia, Elizabeth
    Xu, Xie
    Sheng, Shihong
    Jiang, Yusang
    Liu, Yan
    Han, Chenglong
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3771 - 3773
12345